139 related articles for article (PubMed ID: 2136810)
1. Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.
Reece PA; Olver IN; Morris RG; Bishop JF; Guentert TW; Hill HS; Hillcoat BL
Cancer Chemother Pharmacol; 1990; 25(4):274-8. PubMed ID: 2136810
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of doxifluridine as a five-day stepped-dose continuous infusion.
Olver IN; Reece PA; Bishop JF; Morris RG; Hillcoat BL; Guentert TW
Am J Clin Oncol; 1990 Aug; 13(4):308-11. PubMed ID: 2143051
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of acyclothymidine, a potent pyrimidine nucleoside phosphorylase inhibitor, on the pharmacokinetics of doxifluridine in rabbits via oral administration.
Hamada A; Fukushima S; Morinaga A; Saneyoshi M; Kawaguchi T; Nakano M
Biol Pharm Bull; 1993 Dec; 16(12):1297-300. PubMed ID: 8130783
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase II noncomparative trial of oral and intravenous doxifluridine plus levo-leucovorin in untreated patients with advanced colorectal carcinoma.
Bajetta E; Di Bartolomeo M; Somma L; Moreschi M; Comella G; Turci D; Gebbia V; Scanni A; Bordogna G; Stampino CG
Cancer; 1996 Nov; 78(10):2087-93. PubMed ID: 8918401
[TBL] [Abstract][Full Text] [Related]
5. Disposition and availability of 5-fluorouracil prodrug 5'-deoxy-5-fluorouridine after oral administration in rats.
Au JL
J Pharm Sci; 1987 Sep; 76(9):699-702. PubMed ID: 11002805
[TBL] [Abstract][Full Text] [Related]
6. Doxifluridine in colorectal cancer patients resistant to 5-fluorouracil (5-FU) containing regimens.
Bajetta E; Di Bartolomeo M; Somma L; Del Vecchio M; Artale S; Zunino F; Bignami P; Magnani E; Buzzoni R
Eur J Cancer; 1997 Apr; 33(4):687-90. PubMed ID: 9274455
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of doxifluridine and 5-fluorouracil after single intravenous infusions of doxifluridine to patients with colorectal cancer.
Schaaf LJ; Dobbs BR; Edwards IR; Perrier DG
Eur J Clin Pharmacol; 1988; 34(5):439-43. PubMed ID: 2974418
[TBL] [Abstract][Full Text] [Related]
8. [Usefulness of low dose 5'-DFUR (5'-deoxy-5-fluorouridine) for advanced or recurrent breast cancer].
Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S
Gan To Kagaku Ryoho; 1999 Jun; 26(7):951-8. PubMed ID: 10396323
[TBL] [Abstract][Full Text] [Related]
9. Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.
Au JL; Wientjes MG; Bramer SL
Cancer Chemother Pharmacol; 1988; 22(1):5-10. PubMed ID: 2969304
[TBL] [Abstract][Full Text] [Related]
10. Doxifluridine and leucovorin: an oral treatment combination in advanced colorectal cancer.
Bajetta E; Colleoni M; Di Bartolomeo M; Buzzoni R; Bozzetti F; Doci R; Somma L; Cappuzzo F; Stampino CG; Guenzi A
J Clin Oncol; 1995 Oct; 13(10):2613-9. PubMed ID: 7595715
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of oral doxifluridine in patients with colorectal cancer.
Zampino MG; Colleoni M; Bajetta E; Stampino CG; Guenzi A; de Braud F
Tumori; 1999; 85(1):47-50. PubMed ID: 10228497
[TBL] [Abstract][Full Text] [Related]
12. Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
Iigo M; Nishikata K; Nakajima Y; Hoshi A; Okudaira N; Odagiri H; De Clercq E
Biochem Pharmacol; 1989 Jun; 38(12):1885-9. PubMed ID: 2525905
[TBL] [Abstract][Full Text] [Related]
13. Depression of phenytoin metabolic capacity by 5-fluorouracil and doxifluridine in rats.
Konishi H; Yoshimoto T; Morita K; Minouchi T; Sato T; Yamaji A
J Pharm Pharmacol; 2003 Jan; 55(1):143-9. PubMed ID: 12625878
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological study of 5'-DFUR oral administration and the clinical responses against gastrointestinal carcinoma].
Matsuoka H; Seo Y; Ohshiro T; Adachi E; Nagamine S; Miyazaki N; Shiromizu A; Baba H; Kounoe S; Saito T
Gan To Kagaku Ryoho; 1995 Feb; 22(3):383-8. PubMed ID: 7880109
[TBL] [Abstract][Full Text] [Related]
15. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
Bajetta E; Colleoni M; Rosso R; Sobrero A; Amadori D; Comella G; Marangolo M; Scanni A; Lorusso V; Calabresi F
Eur J Cancer; 1993; 29A(12):1658-63. PubMed ID: 8398289
[TBL] [Abstract][Full Text] [Related]
17. [A study of preoperative administration of 5'-DFUR in patients with colo-rectal cancer].
Haruta A; Umeno T; Tanaka S; Toriya H; Jyozaki H; Ikeda S
Gan To Kagaku Ryoho; 1994 Oct; 21(14):2427-30. PubMed ID: 7944487
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.
Abele R; Alberto P; Seematter RJ; Germano G; Heintz R; Bollag W
Cancer Treat Rep; 1982 Jun; 66(6):1307-13. PubMed ID: 6211232
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial of continuous infusion cyclopentenyl cytosine.
Politi PM; Xie F; Dahut W; Ford H; Kelley JA; Bastian A; Setser A; Allegra CJ; Chen AP; Hamilton JM
Cancer Chemother Pharmacol; 1995; 36(6):513-23. PubMed ID: 7554044
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.
Au JL; Walker JS; Rustum Y
J Pharmacol Exp Ther; 1983 Oct; 227(1):174-80. PubMed ID: 6225866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
